145 related articles for article (PubMed ID: 36482971)
1. Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1.
Sullivan DJ; Franchini M; Senefeld JW; Joyner MJ; Casadevall A; Focosi D
bioRxiv; 2022 Dec; ():. PubMed ID: 36482971
[TBL] [Abstract][Full Text] [Related]
2. Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1.
Sullivan DJ; Franchini M; Senefeld JW; Joyner MJ; Casadevall A; Focosi D
J Gen Virol; 2023 May; 104(5):. PubMed ID: 37167085
[TBL] [Abstract][Full Text] [Related]
3. Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children.
Bellusci L; Grubbs G; Sait S; Yonker LM; Randolph AG; Novak T; Kobayashi T; ; Khurana S
Nat Commun; 2023 Dec; 14(1):7952. PubMed ID: 38040697
[TBL] [Abstract][Full Text] [Related]
4. Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld.
Zhao Q; Wang X; Zhang Z; Liu X; Wang P; Cao J; Liang Q; Qu J; Zhou M
J Med Virol; 2023 Jul; 95(7):e28932. PubMed ID: 37403923
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 Neutralization Capacity in Hemodialysis Patients with and without a Fifth Vaccination with the Updated Comirnaty Original/Omicron BA.4-5 Vaccine.
Liao BH; Platen L; Grommes M; Cheng CC; Holzmann-Littig C; Christa C; Haller B; Kappler V; Bester R; Werz ML; Platen E; Eggerer P; Tréguer L; Küchle C; Schmaderer C; Heemann U; Renders L; Protzer U; Braunisch MC
Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543942
[TBL] [Abstract][Full Text] [Related]
6. Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron.
Amano M; Otsu S; Uemura Y; Ichikawa Y; Matsumoto S; Higashi-Kuwata N; Matsushita S; Shimada S; Mitsuya H
Sci Rep; 2023 Oct; 13(1):17404. PubMed ID: 37833390
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of immune response to SARS-CoV-2 Omicron sublineages six months after different vaccination regimens in Italy.
Trombetta CM; Marchi S; Leonardi M; Coppola C; Benincasa L; Marotta MG; Buonvino N; Maes P; Stufano A; Pontrelli D; Vasinioti VI; Manenti A; Camero M; Montomoli E; Decaro N; Lovreglio P
Acta Trop; 2023 Dec; 248():107042. PubMed ID: 37863379
[TBL] [Abstract][Full Text] [Related]
8. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
Wang Q; Iketani S; Li Z; Liu L; Guo Y; Huang Y; Bowen AD; Liu M; Wang M; Yu J; Valdez R; Lauring AS; Sheng Z; Wang HH; Gordon A; Liu L; Ho DD
Cell; 2023 Jan; 186(2):279-286.e8. PubMed ID: 36580913
[TBL] [Abstract][Full Text] [Related]
9. Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity.
Muik A; Lui BG; Quandt J; Diao H; Fu Y; Bacher M; Gordon J; Toker A; Grosser J; Ozhelvaci O; Grikscheit K; Hoehl S; Kohmer N; Lustig Y; Regev-Yochay G; Ciesek S; Beguir K; Poran A; Vogler I; Türeci Ö; Sahin U
Cell Rep; 2023 Aug; 42(8):112888. PubMed ID: 37527039
[TBL] [Abstract][Full Text] [Related]
10. Omicron BQ.1.1 and XBB.1 unprecedentedly escape broadly neutralizing antibodies elicited by prototype vaccination.
Ju B; Fan Q; Liu C; Shen S; Wang M; Guo H; Zhou B; Ge X; Zhang Z
Cell Rep; 2023 Jun; 42(6):112532. PubMed ID: 37219999
[TBL] [Abstract][Full Text] [Related]
11. A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies against Multiple SARS-CoV-2 Variants including the Currently Circulating Omicron BA.5, BF.7, BQ.1 and XBB.
Ding Y; Fan F; Xu X; Zhao G; Zhang X; Zhao H; Wang L; Wang B; Gao XM
Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112691
[TBL] [Abstract][Full Text] [Related]
12. Immune Evasion of SARS-CoV-2 Omicron Subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a Cohort of Older Adults after ChAdOx1-S Vaccination and BA.4/5 Bivalent Booster.
Machado RRG; Candido ÉD; Aguiar AS; Chalup VN; Sanches PR; Dorlass EG; Amgarten DE; Pinho JRR; Durigon EL; Oliveira DBL
Vaccines (Basel); 2024 Jan; 12(2):. PubMed ID: 38400128
[TBL] [Abstract][Full Text] [Related]
13. Salivary antibodies induced by BA.4/BA.5-convalescence or bivalent booster Immunoglobulin vaccination protect against novel SARS-COV-2 variants of concern.
Diem G; Dichtl S; Zaderer V; Lass-Flörl C; Reindl M; Lupoli G; Dächert C; Muenchhoff M; Graf A; Blum H; Keppler OT; Wilflingseder D; Posch W
Microbiol Spectr; 2023 Aug; 11(5):e0179323. PubMed ID: 37551989
[TBL] [Abstract][Full Text] [Related]
14. Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources.
Sullivan DJ; Franchini M; Joyner MJ; Casadevall A; Focosi D
Nat Commun; 2022 Oct; 13(1):6478. PubMed ID: 36309490
[TBL] [Abstract][Full Text] [Related]
15. Clinical Characteristics and Outcomes of Laboratory-Confirmed SARS-CoV-2 Cases Infected With Omicron Subvariants and the XBB Recombinant Variant.
Karyakarte RP; Das R; Dudhate S; Agarasen J; Pillai P; Chandankhede PM; Labhshetwar RS; Gadiyal Y; Rajmane MV; Kulkarni PP; Nizarudeen S; Joshi S; Potdar V; Karmodiya K
Cureus; 2023 Feb; 15(2):e35261. PubMed ID: 36968876
[TBL] [Abstract][Full Text] [Related]
16. Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources.
Sullivan DJ; Franchini M; Joyner MJ; Casadevall A; Focosi D
medRxiv; 2022 Aug; ():. PubMed ID: 35982681
[TBL] [Abstract][Full Text] [Related]
17. A recombinant spike-XBB.1.5 protein vaccine induces broad-spectrum immune responses against XBB.1.5-included Omicron variants of SARS-CoV-2.
He C; Alu A; Lei H; Yang J; Hong W; Song X; Li J; Yang L; Wang W; Shen G; Lu G; Wei X
MedComm (2020); 2023 Jun; 4(3):e263. PubMed ID: 37125241
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations.
Hyun HJ; Choi MJ; Nham E; Seong H; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Yoon SK; Park SJ; Gwak WS; Lee JW; Kim BG; Song JY
Vaccines (Basel); 2023 Aug; 11(8):. PubMed ID: 37631890
[TBL] [Abstract][Full Text] [Related]
19. A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates.
Liu Z; Zhou J; Wang X; Xu W; Teng Z; Chen H; Chen M; Zhang G; Wang Y; Huang J; Wang Q; Jiang S; Lu L
Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2221713120. PubMed ID: 36897979
[TBL] [Abstract][Full Text] [Related]
20. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Lye DC; Tan KB
Lancet Infect Dis; 2023 Jul; 23(7):799-805. PubMed ID: 36924786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]